nach oben

Erschienen in:

02.01.2019 | Original Article

Multi-gene panel testing confirms phenotypic variability in MUTYH-Associated Polyposis

verfasst von: Erin G. Sutcliffe, Amanda Bartenbaker Thompson, Amy R. Stettner, Megan L. Marshall, Maegan E. Roberts, Lisa R. Susswein, Ying Wang, Rachel T. Klein, Kathleen S. Hruska, Benjamin D. Solomon

Erschienen in: Familial Cancer | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Biallelic pathogenic variants (PVs) in MUTYH cause MUTYH-Associated Polyposis (MAP), which displays phenotypic overlap with other hereditary colorectal cancer (CRC) syndromes including Familial Adenomatous Polyposis (FAP) and Lynch syndrome. We report the phenotypic spectrum of MAP in the context of multi-gene hereditary cancer panel testing. Genetic testing results and clinical histories were reviewed for individuals with biallelic MUTYH PVs detected by panel testing at a single commercial molecular diagnostic laboratory. Biallelic MUTYH PVs were identified in 82 individuals (representing 0.2% of tested individuals) with most (75/82; 91.5%) reporting a personal history of CRC and/or polyps. Ten percent (6/61) of individuals reporting polyp number reported fewer than 10 polyps and therefore did not meet current MAP testing criteria. Extracolonic cancers (21/82; 25.6%), multiple primaries (19/82; 23.2%), Lynch-like (17/82; 20.7%) and FAP-like phenotypes (16/82; 19.5%) were observed, including individuals with mismatch repair-deficient tumors (3/82; 3.7%), sebaceous neoplasms (2/82; 2.4%), or congenital hypertrophy of the retinal pigment epithelium (CHRPE) (2/82; 2.4%). We report what is to our knowledge the first cohort of individuals with MAP identified by panel testing. The phenotypic spectrum of MAP observed in this cohort aligns with the published literature. In addition to standard indications for MUTYH testing, our data provide evidence to support consideration of MAP in the differential diagnosis for some individuals with fewer than 10 polyps, depending on other personal and/or family history, as well as for individuals suspected to have Lynch syndrome or FAP.

Nur mit Berechtigung zugänglich

Jenkins MA, Croitoru ME, Monga N et al (2006) Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 15:312–314. https://doi.org/10.1158/1055-9965.EPI-05-0793 CrossRef

Goodenberger M, Lindor NM (2011) Lynch syndrome and MYH-associated polyposis: review and testing strategy. J Clin Gastroenterol 45:488–500. https://doi.org/10.1097/MCG.0b013e318206489c CrossRefPubMed

Farrington SM, Tenesa A, Barnetson R et al (2005) Germline susceptibility to colorectal cancer due to base-excision repair gene defects. Am J Hum Genet 77:112–119. https://doi.org/10.1086/431213 CrossRefPubMedPubMedCentral

Balaguer F, Castellví-Bel S, Castells A et al (2007) Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 5:379–387. https://doi.org/10.1016/j.cgh.2006.12.025 CrossRef

Morak M, Laner A, Bacher U et al (2010) MUTYH-associated polyposis—variability of the clinical phenotype in patients with biallelic and monoallelic MUTYH mutations and report on novel mutations. Clin Genet 78:353–363. https://doi.org/10.1111/j.1399-0004.2010.01478.x CrossRefPubMed

Leoz ML, Carballal S, Moreira L et al (2015) The genetic basis of familial adenomatous polyposis and its implications for clinical practice and risk management. Appl Clin Genet 8:95–107. https://doi.org/10.2147/TACG.S51484 CrossRefPubMedPubMedCentral

Barnetson RA, Devlin L, Miller J et al (2007) Germline mutation prevalence in the base excision repair gene, MYH, in patients with endometrial cancer. Clin Genet 72:551–555. https://doi.org/10.1111/j.1399-0004.2007.00900.x CrossRefPubMed

Tricarico R, Bet P, Ciambotti B et al (2009) Endometrial cancer and somatic G> T KRAS transversion in patients with constitutional MUTYH biallelic mutations. Cancer Lett 274:266–270. https://doi.org/10.1016/j.canlet.2008.09.022 CrossRefPubMed

Vogt S, Jones N, Christian D et al (2009) Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 137:1976–1985.e1. https://doi.org/10.1053/j.gastro.2009.08.052 CrossRefPubMed

10.

Win AK, Reece JC, Dowty JG et al (2016) Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH. Int J Cancer 139:1557–1563. https://doi.org/10.1002/ijc.30197 CrossRefPubMedPubMedCentral

11.

Castillejo A, Vargas G, Castillejo MI et al (2014) Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. Eur J Cancer Oxf Engl 1990 50:2241–2250. https://doi.org/10.1016/j.ejca.2014.05.022 CrossRef

12.

NCCN Guidelines. Genetic/Familial High-Risk Assessment: Colorectal (Version 3.2017). http://www.nccn.org/clinical.asp. Accessed 19 Jun 2017

13.

Nielsen M, Lynch H, Infante E, Brand R (2015) MUTYH-associated polyposis. In: Adam MP, Ardinger HH, Pagon RA et al (eds) GeneReviews®. University of Washington, Seattle

14.

Wallis YL, Macdonald F, Hultén M et al (1994) Genotype-phenotype correlation between position of constitutional APC gene mutation and CHRPE expression in familial adenomatous polyposis. Hum Genet 94:543–548CrossRefPubMed

15.

Coleman P, Barnard NAS (2007) Congenital hypertrophy of the retinal pigment epithelium: prevalence and ocular features in the optometric population. Ophthalmic Physiol Opt J Br Coll Ophthalmic Opt Optom 27:547–555. https://doi.org/10.1111/j.1475-1313.2007.00513.x CrossRef

16.

Sieber OM, Lipton L, Crabtree M et al (2003) Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 348:791–799. https://doi.org/10.1056/NEJMoa025283 CrossRefPubMed

17.

Gismondi V, Meta M, Bonelli L et al (2004) Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas. Int J Cancer 109:680–684. https://doi.org/10.1002/ijc.20054 CrossRefPubMed

18.

Eliason K, Hendrickson BC, Judkins T et al (2005) The potential for increased clinical sensitivity in genetic testing for polyposis colorectal cancer through the analysis of MYH mutations in North American patients. J Med Genet 42:95–96. https://doi.org/10.1136/jmg.2004.025973 CrossRefPubMedPubMedCentral

19.

Riegert-Johnson DL, Johnson RA, Rabe KG et al (2007) The value of MUTYH testing in patients with early onset microsatellite stable colorectal cancer referred for hereditary nonpolyposis colon cancer syndrome testing. Genet Test 11:361–365. https://doi.org/10.1089/gte.2007.0014 CrossRefPubMed

20.

Pearlman R, Frankel WL, Swanson B et al (2017) Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol 3:464–471. https://doi.org/10.1001/jamaoncol.2016.5194 CrossRefPubMedPubMedCentral

21.

Morak M, Heidenreich B, Keller G et al (2014) Biallelic MUTYH mutations can mimic Lynch syndrome. Eur J Hum Genet EJHG 22:1334–1337. https://doi.org/10.1038/ejhg.2014.15 CrossRefPubMed

22.

Seguí N, Navarro M, Pineda M et al (2015) Exome sequencing identifies MUTYH mutations in a family with colorectal cancer and an atypical phenotype. Gut 64:355–356. https://doi.org/10.1136/gutjnl-2014-307084 CrossRefPubMed

23.

Kacerovska D, Drlik L, Slezakova L et al (2016) Cutaneous sebaceous lesions in a patient with MUTYH-associated polyposis mimicking Muir-Torre syndrome. Am J Dermatopathol 38:915–923. https://doi.org/10.1097/DAD.0000000000000649 CrossRefPubMed

24.

Roberts ME, Riegert-Johnson DL, Thomas BC et al (2013) Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms. J Genet Couns 22:393–405. https://doi.org/10.1007/s10897-012-9552-4 CrossRefPubMed

25.

Landon M, Ceulemans S, Saraiya DS et al (2015) Analysis of current testing practices for biallelic MUTYH mutations in MUTYH-associated polyposis. Clin Genet 87:368–372. https://doi.org/10.1111/cge.12375 CrossRefPubMed

26.

Susswein LR, Marshall ML, Nusbaum R et al (2016) Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med Off J Am Coll Med Genet 18:823–832. https://doi.org/10.1038/gim.2015.166 CrossRef

27.

Roberts ME, Jackson SA, Susswein LR et al (2018) MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer. Genet Med Off J Am Coll Med Genet. https://doi.org/10.1038/gim.2017.254 CrossRef

28.

SEER 9 Regs Research Data Surveillance, Epidemiology, and End Results (SEER) Program (http://www.seer.cancer.gov) SEER*Stat Database: Incidence—SEER 9 Regs Research Data, Nov 2017 Sub (1973-2015) <Katrina/Rita Population Adjustment>—Linked To County Attributes—Total U.S., 1969-2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission.

29.

Cleary SP, Cotterchio M, Jenkins MA et al (2009) Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology 136:1251–1260. https://doi.org/10.1053/j.gastro.2008.12.050 CrossRefPubMed

30.

Lek M, Karczewski KJ, Minikel EV et al (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature 536:285–291. https://doi.org/10.1038/nature19057 CrossRefPubMedPubMedCentral

31.

Win AK, Dowty JG, Cleary SP et al (2014) Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology 146:1208–1211.e1–e5. https://doi.org/10.1053/j.gastro.2014.01.022.CrossRefPubMedPubMedCentral

32.

Elsaid A, Elshazli R, El-Tarapely F et al (2017) Association of monoallelic MUTYH mutation among Egyptian patients with colorectal cancer. Fam Cancer 16:83–90. https://doi.org/10.1007/s10689-016-9927-z CrossRefPubMed

33.

Lubbe SJ, Di Bernardo MC, Chandler IP, Houlston RS (2009) Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol Off J Am Soc Clin Oncol 27:3975–3980. https://doi.org/10.1200/JCO.2008.21.6853 CrossRef

34.

Win AK, Hopper JL, Jenkins MA (2011) Association between monoallelic MUTYH mutation and colorectal cancer risk: a meta-regression analysis. Fam Cancer 10:1–9. https://doi.org/10.1007/s10689-010-9399-5 CrossRefPubMedPubMedCentral

Titel: Multi-gene panel testing confirms phenotypic variability in MUTYH-Associated Polyposis
verfasst von: Erin G. Sutcliffe
Amanda Bartenbaker Thompson
Amy R. Stettner
Megan L. Marshall
Maegan E. Roberts
Lisa R. Susswein
Ying Wang
Rachel T. Klein
Kathleen S. Hruska
Benjamin D. Solomon
Publikationsdatum: 02.01.2019
Verlag: Springer Netherlands
Erschienen in: Familial Cancer / Ausgabe 2/2019
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-018-00116-2

Springer Medizin

Multi-gene panel testing confirms phenotypic variability in MUTYH-Associated Polyposis

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Recent advances in Lynch syndrome

Genetic counselling of young women with breast cancer for Li–Fraumeni syndrome: a nationwide survey on the experiences and attitudes of genetics professionals

Risk of multiple colorectal cancer development depends on age and subgroup in individuals with hereditary predisposition

Massive juvenile polyposis of the stomach in a family with SMAD4 gene mutation

Cleft lip/palate and hereditary diffuse gastric cancer: report of a family harboring a CDH1 c.687 + 1G > A germline mutation and review of the literature

Monoallelic MUTYH carrier status is not associated with increased breast cancer risk in a multigene panel cohort

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie